Cargando…

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Baar, Michaël J. B., van der Aart, Annemarie B., Hoogenberg, Klaas, Joles, Jaap A., Heerspink, Hiddo J. L., van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657126/ https://www.ncbi.nlm.nih.gov/pubmed/31384419 http://dx.doi.org/10.1177/2042018819865398

Ejemplares similares

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2021)

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
por: van der Aart ‐ van der Beek, Annemarie B., et al.
Publicado: (2020)

Renal haemodynamic response to sodium‐glucose cotransporter‐2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2021)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Reprogramming: A Preventive Strategy in Hypertension Focusing on the Kidney
por: Tain, You-Lin, et al.
Publicado: (2015)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP-1R Signaling and Functional Molecules in Incretin Therapy
por: Wan, Wenwei, et al.
Publicado: (2023)

Editorial: Incretin agonists in the treatment of obesity
por: Sun, Xiaodong, et al.
Publicado: (2023)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 Inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2020)

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
por: Marathe, Chinmay S., et al.
Publicado: (2011)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
por: van der Hoek, Sjoukje, et al.
Publicado: (2023)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
por: van der Aart‐van der Beek, Annemarie B., et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
por: Zhang, Zeqing, et al.
Publicado: (2017)

Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine
por: Kaneto, Hideaki, et al.
Publicado: (2021)

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
por: de Boer, Stefanie Amarens, et al.
Publicado: (2015)

Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets
por: van de Wouw, Jens, et al.
Publicado: (2019)

A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?
por: Butler, Peter C., et al.
Publicado: (2013)

GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics
por: Wright, Shane C., et al.
Publicado: (2023)

Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
por: Scholtes, Rosalie A., et al.
Publicado: (2022)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Incretins in the Therapy of Diabetic Kidney Disease
por: Przezak, Agnieszka, et al.
Publicado: (2021)

Dissecting recipient from donor contribution in experimental kidney transplantation: focus on endothelial proliferation and inflammation
por: Papazova, Diana A., et al.
Publicado: (2018)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m9d4o0bh2ecapvg0ctiealpo6g